Ryan Flinn News
-
BioMarin Pharmaceutical Inc., a maker of drugs for rare diseases, rose the most in more than six months ahead of a medical conference where the company plans to publish data on its experimental cancer therapy.
-
Dendreon Corp., maker of the prostate cancer drug Provenge, fell the most in nine months after the company failed to meet analysts’ revenue estimates.
-
Health Management Associates Inc., an operator of 71 hospitals in the U.S., said its accounting procedures, including payments from government health programs, are being investigated by federal regulators.
-
Gilead Sciences Inc., the world’s biggest maker of AIDS medicines, reported first-quarter profit that missed analysts’ estimates on declining sales of its HIV drugs.
-
Gilead Sciences Inc. rose to its highest price ever on optimism over potential sales for the company’s experimental hepatitis C medications.
-
Arena Pharmaceuticals Inc., the maker of the weight-loss drug Belviq, said it is withdrawing its application to gain regulatory approval in Europe for the obesity medicine.
-
Gilead Sciences Inc. is moving its experimental drug combination against hepatitis C into a late- stage trial after it cured 95 percent of patients who used the medicine for eight weeks.
-
Actavis Inc., the generic drugmaker whose merger negotiations with Valeant Pharmaceuticals International Inc. stalled over price, may deserve the industry’s second-best valuation ever in a deal.
-
Expanding Medicaid plans for the poor won’t always improve the physical health of enrollees, though it may save them from financial ruin, a study in Oregon found.
-
Amgen Inc., the world’s largest biotechnology company, declined the most in four years after reporting sales growth that missed analysts’ estimates.
|
|
Most Popular on Bloomberg
|
| |
Rate this Page